Cluster of Differentiation (CD) Antibodies: Core Reagents to Decode Comprehensive Immune Cell Identity Landscapes

Definition & Fundamental Biological Roles of CD Cluster Differentiation Molecules

Cluster of Differentiation (CD) markers form a unified standardized classification system for surface glycoproteins expressed across all hematopoietic cell lineages, including lymphocytes, myeloid subsets, dendritic cells and thrombocytes. Hundreds of distinct CD antigens mediate core biological events such as cell adhesion, chemotaxis, TCR signal transduction and immune cell activation cascades beyond simple lineage labeling. Precise CD marker immunophenotyping serves as the foundational experimental workflow for immune subset identification, developmental trajectory tracing and inflammatory tumor microenvironment characterization. Advances in multi-spectral flow cytometry and single-cell sequencing generate rising global demand for customized CD antibody clones with verified specificity across human, mouse and primate biospecimens. Validated CD antibody panels eliminate ambiguous cell population gating and deliver quantitative cell frequency readouts for longitudinal immunology research cohorts.

CD Antibody Panels for Lymphocyte Subset Immunophenotyping

T Cell Lineage Classification Workflows

CD3 acts as the pan-T lineage defining marker to separate all T lymphocytes from other leukocyte populations. CD4 and CD8 antibodies divide mature T cells into helper and cytotoxic core subgroups for functional co-culture assays. Combined CD45RA and CCR7 staining distinguishes four developmental stages: naive, central memory, effector memory and terminally differentiated effector T cells. Custom CD4/RORγt dual antibody cocktails quantify Th17 cell abundance within autoimmune disease tissue specimens. Tumor immunology co-staining schemes pair CD8 with PD-1, TIM-3 and LAG-3 antibodies to enumerate exhausted cytotoxic T cell infiltration gradients in solid tumor spheroids.

B Cell Developmental Profiling

CD19 serves as universal pan-B cell surface marker from progenitor stages to mature circulating B lymphocytes. CD20 labels immature and mature B subsets while CD27 exclusively marks long-lived memory B populations. CD38 and CD138 antibodies identify terminally differentiated plasma cells within bone marrow and peripheral blood mononuclear cell samples. Multiplex CD antibody panels resolve sequential B cell maturation stages including pro-B, pre-B, transitional and naive subsets for humoral immunity mechanistic research.

NK Cell Functional Subset Stratification

CD56 and CD16 antibody combinations split natural killer cells into two functionally distinct subpopulations. CD56bright CD16dim subsets dominate immunoregulatory cytokine secretion, whereas CD56dim CD16bright cells execute robust target cell cytotoxicity. Additional CD94 antibody co-staining further refines NK cell maturation status during chronic viral infection co-culture monitoring experiments.

CD Antibody Reagents for Myeloid Cell Subtype Distinction

Monocyte & Macrophage Polarization Assays

CD14 labels classical circulating monocytes while CD16 identifies non-classical monocyte subpopulations in human plasma samples. CD68 acts as pan-macrophage tissue marker; CD86 antibody detects M1 pro-inflammatory polarized macrophages, and CD163/CD206 pairs quantify anti-inflammatory M2 macrophage abundance within tumor stromal microenvironments. Serial CD marker staining tracks dynamic macrophage polarization shifts after cytokine or small molecule compound stimulation cycles.

Dendritic Cell Immunophenotyping

CD11c and CD1c serve as signature markers for conventional myeloid dendritic cell subsets. CD123 paired with CD303 plasmacytoid DC antibodies enables separation of type I interferon-producing dendritic populations in infectious disease research. Multi-color CD antibody panels map DC spatial distribution within lymph node and tumor tissue cross-sections via immunofluorescence imaging.

Granulocyte Subset Identification

CD66b and CD15 antibodies specifically label neutrophil populations for inflammatory tissue infiltration quantification. CD16 and CD125 co-staining identifies eosinophil granulocytes, while CD123/CD203c combinations distinguish basophil subsets in allergy mechanism cell culture assays.

CD Antibody Applications for Immune Checkpoint & Co-Stimulation Research

Inhibitory immune checkpoint receptors including PD-1, CTLA-4, LAG-3 and TIGIT represent critical CD-family related targets for tumor immunology screening. CD antibody cocktails measure checkpoint molecule surface density on tumor-infiltrating T cells to quantify lymphocyte exhaustion severity gradients. Co-stimulatory CD markers CD28, ICOS, OX40 and 4-1BB enable evaluation of T cell activation magnitude post antigen stimulation in vaccine research models. Serial CD checkpoint antibody staining tracks functional recovery after checkpoint blockade antibody co-incubation within long-term co-culture systems.

CD Antibody Panels for Hematopoietic Tumor Subtyping Research

Multi-marker CD antibody combinations form standard immunophenotyping workflows for hematologic malignant cell line characterization. B cell lymphoma detection panels utilize CD19, CD20, CD10, CD5 and CD23 antibody clones for subtype stratification. T cell lymphoma profiling relies on CD3, CD4, CD8, CD7 and CCR7 CD marker cocktails. Acute myeloid leukemia identification employs CD13, CD33, CD34 and CD117 antibodies to separate blast cell populations from normal myeloid precursors. Multiple myeloma screening uses CD38, CD138 and BCMA CD reagents to quantify malignant plasma cell frequency in bone marrow biospecimens. These CD antibody panels support minimal residual disease monitoring in sequential longitudinal sample analysis pipelines.

Custom CD Antibody Development Service from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. delivers full-spectrum one-stop custom CD antibody development workflows built on proprietary recombinant rabbit and single B cell technical platforms. The integrated service pipeline covers target antigen design, animal immunization, high-throughput B cell sorting, antibody gene cloning and mammalian cell recombinant expression. Multi-step chromatographic purification generates antibody stocks exceeding 95% purity with endotoxin concentrations maintained below 1.0 EU/μg. All custom CD clones undergo orthogonal validation across WB, IHC, immunofluorescence and multi-color flow cytometry platforms before delivery. Flexible production formats include full-length IgG, Fab and scFv variants with optional biotin, fluorophore or Fc fusion labeling to match distinct experimental screening requirements.

Core Research Applications of Custom CD Antibodies from ANT BIO PTE. LTD.

High-dimensional spectral flow cytometry immunophenotyping utilizing customized CD marker panels to resolve rare innate and adaptive immune cell subsets. FFPE tissue microarray immunofluorescence co-staining maps spatial immune cell infiltration patterns within solid tumor and inflammatory organ specimens. Immunoprecipitation assays characterize CD surface receptor intracellular signal transduction complexes under stimulated culture conditions. Preclinical therapeutic antibody candidate screening uses custom CD clones for target binding affinity and neutralization functional testing. Hematological tumor cell line profiling stratifies malignant blast populations via standardized CD antibody biomarker readouts. CAR-T cell engineering workflows employ custom CD antibodies to verify chimeric receptor surface expression levels on engineered lymphocyte populations.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.